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skeleton in 10 cases and long bones in eight cases. Eleven cases were metastatic at initial presentation, 10 with pulThere were nine females. The median age at diagnosis was 14.2 years (range 2.75-30 years). There was one monary disease and one with bone marrow involvement. The primary tumour of the metastatic cases was central early death due to cytomegalovirus pneumonitis. One patient developed a single generalised convulsion during skeleton in six, and long bones in five cases. Six of the seven non-metastatic patients had bulky primary tumours busulphan therapy. Severe renal toxicity was not encountered. One patient developed veno-occlusive dis-(у100 ml) and the seventh patient was in second complete remission at the time of high-dose therapy. In total 12 ease of the liver (VOD) which eventually resolved. With a median follow up of 2 years, 13 patients survive patients were in first complete remission (CR1), four in CR2, one in partial remission (PR) and one with progressincluding six with initial metastatic disease. We conclude that high-dose busulphan/melphalan is well-tolerive disease (PD) at the time of HDT. The characteristics of these patients including their initial chemotherapy are ated and should be evaluated for efficacy in a larger series of patients with high risk Ewing's sarcoma.
shown in Table 1 . Pretreatment investigations besides clinical evaluation Keywords: busulphan/melphalan; high-risk Ewing's sarcoma; autologous stem cell rescue included radiological assessment (CT scan and/or MRI) of all measurable disease, haematological and biochemical parameters, bone marrow aspirate/trephine and assessment of renal function including glomerular filtration rate. Daily The introduction of combined modality treatment has led measurement of haematological and biochemical parato a rapid improvement in the prognosis for many patients meters were done from day 1 post-stem cell re-infusion with Ewing's sarcoma.
1-3 However, the results from indiuntil recovery. Informed verbal consent regarding the use vidual centres and cooperative groups have consistently of the drug combination and stem cell harvest procedure identified the inferior prognosis of patients with large volwas obtained from the parents, or patients, of all cases ume primary tumours and/or metastatic disease. 4, 5 entered into the study. High-dose chemotherapy with autologous stem cell rescue (bone marrow and more recently peripheral blood stem Treatment cell (PBSC)) is under evaluation in the management of many cancers, particularly haematological malignancies. [6] [7] [8] [9] All patients were treated with busulphan 16 mg/kg (14 Ewing's sarcoma may be a suitable disease for this strategy patients) or 600 mg/m 2 (four patients), orally over 4 days because of its sensitivity to alkylating agents. Several small in 6 hourly divided doses, after 12 h prehydration, from studies have suggested that some patients with poor risk day −5 to −2 prior to stem cell re-infusion. This was folEwing's sarcoma may benefit from high-dose therapy. [10] [11] [12] [13] lowed by the intravenous infusion of melphalan at a dose The combination of busulphan/melphalan has been used in of 160 mg/m 2 (11 patients) or 140 mg/m 2 (six patients) on patients with acute or chronic myeloid leukaemia and other day −1. Cryopreserved autologous stem cells, bone marrow solid tumours. [14] [15] [16] This report describes the combined (BM) (seven patients), peripheral blood stem cells (PBSC) experience of two centres using a single regimen, busul-(seven patients) or both (four patients), were infused on the phan and melphalan followed by autologous stem cell following day (DO), at least 48 h after completion of the rescue in patients with Ewing's sarcoma.
busulphan course (Table 2) . PBSC were harvested without the use of growth factors in 11 patients and cyclophosphamide and G-CSF priming 844 Table 1 Details of patients and prior treatment usually performed on two separate occasions to maximise mononuclear cell counts. Phenytoin at a dose 8 mg/kg/day orally in two divided doses was commenced 2 weeks prior to busulphan as prophylaxis against neurotoxicity and continued until 48 h after the last dose of busulphan. No prophylactic antibiotics were used. Only one patient received G-CSF (5 g/kg/day) post-stem cell rescue from day +10. years) after high-dose therapy there are 13 surviving course of systemic antibiotics for episodes of febrile neutroetoposide with encouraging results as compared to historical control groups. 18, 19 penia with addition of systemic antifungal agents in the majority of patients. One patient developed clinical and bioOther nonrandomised studies using high-dose alkylating agents ± TBI failed to demonstrate any benefit in poor risk chemical features of VOD which resolved. Another patient developed haemorrhagic cystitis which continues to recur patients. 20 The combination of busulphan/melphalan has been used in patients with myeloid malignancies and other but which required no intervention.
solid tumours with acceptable toxicity and anti-tumour activity. 14-16 Analysis of the European Bone Marrow Transplant registry (EBMT) data showed that consolidation of Discussion remission with busulphan/melphalan and autologous stem cell rescue in children with high-risk Ewing's sarcoma who The definition of high risk Ewing's sarcoma varies between were treated with a wide range of initial chemotherapy lead study groups. In general, those with bulky primary tumours to a 5-year EFS of 51% with acceptable toxicity. 19 The (у100 ml tumour volume) do poorly and those with bone avoidance of TBI should help to reduce the long-term sidemarrow or bone involvement are unlikely to be cured with effects particularly the effect on growth and endocrine conventional therapy. The UKCCSG experience indicates functions. that only 10-20% with lung metastases at diagnosis survive
In the present study, busulphan was given in divided long term and those with bone metastases were all dead doses over 4 days, a schedule based on experience in leuat 30 months from diagnosis. 5 In some studies the use of kaemia. Phenytoin was used as an anticonvulsant during ifosfamide to replace cyclophoshamide has been associated busulphan therapy to prevent neurological toxicity. It has, with an increase in overall survival and EFS but with however, been found that phenytoin may enhance the increased morbidity, mainly tubular nephropathy. 5, 17 metabolism of busulphan and we have recently changed to The German (CESS 81) study confirmed the adverse the use of clonazepam to avoid this complication.
21
prognostic significance of bulky tumours (у100 ml) and The kinetics of high-dose busulphan have now been poor response to chemotherapy (more than 10% viable widely studied in children. The short half-life of the drug tumour in the resected specimens) with DFS at 3 years of in children, due to its rapid clearance, leads to a lower area 31% compared to 79% for patients with small tumours or under the concentration curve (AUC) than in adults. Consewith less than 10% viable tumours in the resected tumour. 1 quently, when based on weight alone a relatively lower In the follow-up study (CESS 86) ifosfamide replaced AUC is achieved. [22] [23] [24] This may not only explain the lower cyclophosphamide and local therapy (surgery ± incidence of neurological toxicity in small children than in radiotherapy) was brought forward to week 9. Also, adults but could lead to a lower therapeutic effect. A dose patients were randomised to conventional or hyperfractionbased on surface area has therefore been developed and ated radiotherapy with four-drug chemotherapy continued shown to produce more consistent AUC levels. 22, 23 This throughout. EFS for patients with tumours у100 ml strategy leads to increased toxicity but improved efficacy increased from 32 to 66% with no difference between the
has not yet been demonstrated. two RT arms in terms of survival or toxicity. It was conIn the present study drugs were well tolerated. Toxicity cluded that patients with larger tumours may benefit from was acceptable, with only one procedure-related mortality intensified chemotherapy.
(5.5%) and no significant renal or (fatal) hepatic toxicity. High-dose chemotherapy with or without radiotherapy Thirteen patients remain in complete remission including and autologous stem cell rescue is being increasingly used six with metastatic disease at presentation (Figure 1 ). The in many childhood cancers. Several small studies have sugmedian survival of metastatic patients is 3 years and 9 gested that some patients with poor risk Ewing's sarcoma months from the time of megatherapy with a median may benefit from this modality. [10] [11] [12] [13] Most published data progression-free survival of 1 year 5 months (Figure 2 ). involve TBI-based regimens using melphalan/TBI/ Compared to historical controls, these data show promising disease control rates. The role of HDC in Ewing's sarcoma merits evaluation in an unselected group of clearly defined poor risk patients, possibly with a randomised question regarding the value of TBI in the treatment regimen. Such a study would require international collaboration. 
